Results 281 to 290 of about 731,872 (346)

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

open access: yesAdvanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li   +10 more
wiley   +1 more source

NSUN5 Attenuates Renal Injury and Ferroptosis in Hyperuricaemic Nephropathy Through YBX2‐Dependent Stabilisation of SCD1 m5C Methylation

open access: yesAdvanced Science, EarlyView.
NSUN5 is downregulated in hyperuricaemic nephropathy. Overexpression of NSUN5 enhances the stability of SCD1 mRNA through the m5C reader YBX2, ultimately inhibiting ferroptosis in renal tubular epithelial cells. Additionally, this axis suppresses the NF‐κB signaling pathway to alleviate inflammation and upregulates ABCG2 to promote uric acid excretion,
Xiu‐xiu Song   +12 more
wiley   +1 more source

Single‐Cell Dissection of Tumor‐Infiltrating Lymphocytes Reveals Cellular Architecture Predictive of Therapeutic Efficacy in Acral Melanoma

open access: yesAdvanced Science, EarlyView.
Autologous tumor‐infiltrating lymphocyte (TIL) therapy shows promising efficacy in acral melanoma, yet determinants of durable response remain unclear. By integrating single‐cell transcriptomics and TCR sequencing, this study reveals that TIL products enriched for T follicular helper and intermediate exhausted T cells establish persistent clonal ...
Chao Zhang   +12 more
wiley   +1 more source

First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria

open access: yesAdvanced Science, EarlyView.
We report the first PROTACs designed to degrade progerin, introducing a novel therapeutic approach for progeria. The best compound, UCM‐18142, significantly reduces progerin levels and improves key disease phenotypes in patient‐derived cells and in the LmnaG609G/G609G mouse model, paving the way for new treatment strategies targeting the root cause of ...
Jon Macicior‐Michelena   +5 more
wiley   +1 more source

Interleukin-6 and interleukin-6 receptor gene expression in pituitary tumors

Journal of Neuro-Oncology, 1994
Interleukin-6 (IL-6) is a multifunctional cytokine which plays a role in the stimulation, inhibition, differentiation, and regulation of cell growth. IL-6 has been shown to act as an autocrine growth factor in several tumors, and is expressed by a variety of tumors. IL-6 also exhibits a regulatory role in the hypothalamo-pituitary axis.
A R, Rezai   +4 more
openaire   +2 more sources

Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease

Neuroscience Letters, 1998
Serum levels of interleukin-6 (IL-6) and interleukin-6 soluble receptor (IL-6sR) were measured in 41 patients (23 female and 18 male, mean age 72.5 years) with Alzheimer's disease (AD) and in 32 controls (14 women and 18 men, mean age 69.2 years) using enzyme-linked immunosorbent assays (ELISA).
P, Angelis   +4 more
openaire   +2 more sources

Serum Interleukin-6, Soluble Interleukin-6 Receptor and Crohn’s Disease Activity

Digestive Diseases and Sciences, 2007
The relationship between plasma interleukin-6 (IL-6) concentration and its soluble receptor in Crohn's disease (CD) is not well elucidated. Twenty healthy volunteers and 94 consecutive patients with CD (44 in relapse and 50 in remission) were studied. Plasma IL-6 concentrations in patients with active disease [80 +/- 9 pg/ml; mean +/- standard error of
Stéphane, Nancey   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy